The aim of this study was to evaluate whether proconvulsive interleukin-1β (IL-1β) and anticonvulsive IL-1 receptor antagonist (IL-1Ra) are markers of the effectiveness of treatment in patients with West syndrome (WS). We analyzed serum and cerebrospinal fluid (CSF) levels of IL-1β and IL-1Ra in 13 patients with WS. The serum IL-1Ra levels postimprovement (average, 384.6 pg/ml) in clinical and electroencephalographic (EEG) findings were significantly higher than the preimprovement values (average, 240.6 pg/ml). No significant difference in the preimprovement serum IL-1Ra levels was noted between the anticonvulsant (AED)-response and adrenocorticotropic hormone (ACTH)-response groups (260.0 pg/ml, n=7 vs. 218.0 pg/m, n=6) and the cryptogenic and symptomatic groups (290.1 pg/ml, n=4 vs. 218.3 pg/m, n=9), respectively; as for the preimprovement CSF levels, the AED-response group (114.5 pg/m; n=3) and ACTH-response groups (138.0 pg/m; n=6) and the cryptogenic (59.3 pg/m; n=3) and symptomatic groups (165.6 pg/m; n=6), respectively. Serum and CSF IL-1β levels were detected only in 3 patients preimprovement. Serum IL-1Ra levels were elevated subsequent to resolution of clinical and EEG findings in WS patients. A larger study should be conducted to clarify whether an immunological processes are concerned with the pathophysiology of WS.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of the Neurological Sciences
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures.J Neurosci. 1999; 19: 5054-5065
- Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice.Proc Natl Acad Sci USA. 2000; 97: 11534-11539
- Cerebrospinal fluid diacron-reactive oxygen metabolite levels in pediatric patients with central nervous system diseases.Pediatr Neurol. 2008; 39: 80-84
- Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy.Epilepsia. 2006; 47: 1160-1168
- Interleukin converting enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1beta production.Neurobiol Dis. 2008; 31: 327-333
- Interleukin-6 and interleukin-1 receptor antagonist in cerebrospinal fluid from patients with recent tonic-clonic seizures.Epilepsy Res. 2000; 41: 205-211
- Increased plasma levels of cytokines after seizures in localization-related epilepsy.Acta Neurol Scand. 2007; 116: 226-230
- Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder.J ECT. 2008; 24: 88-91
- Levels of IL-1beta and IL-1ra in cerebrospinal fluid of human patients after single and prolonged seizures.Neuroimmunomodulation. 2010; 17: 19-22
- The IL-1beta system in epilepsy-associated malformations of cortical development.Neurobiol Dis. 2006; 24: 128-143
- Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy.Neurobiol Dis. 2008; 29: 142-160
- Serum cytokine levels are altered in patients with West syndrome.Brain Dev. 2001; 23: 548-551
- Immunologic aspects of West syndrome and evidence of plasma inhibitory effects on T cell function.Arq Neuropsiquiatr. 2003; 61: 731-737
- Cerebrospinal fluid interleukin-6 levels in patients with West syndrome.Brain Dev. 2006; 28: 19-23
- Reduced levels of interleukin-1 receptor antagonist in the cerebrospinal fluid in patients with West syndrome.Epilepsy Res. 2009; 85: 314-317
Shiihara T, Miyashita M, Yoshizumi M, Watanabe M, Yamada Y, Kato M. Peripheral lymphocyte subset and serum cytokine profiles of patients with West syndrome. Brain Dev 2009. Epub 2009 Dec 1.
- A pilot study on the changes in immunity after ACTH therapy in patients with West syndrome.Brain Dev. 2009; 31: 739-743
- A prospective study of infantile spasms: clinical and therapeutic correlations.Epilepsia. 1983; 24: 135-158
- Remission associated with human herpesvirus infection in west syndrome.J Child Neurol. 2006; 21: 886-890
- Interleukin-6, interleukin-1 receptor antagonist and interleukin-1beta production in patients with focal epilepsy: a video-EEG study.J Neurol Sci. 2009; 280: 94-97
- Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo.Blood. 1994; 84: 2136-2143
- A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?.Blood. 2007; 109: 155-158
- Differential regulation of interleukin-1 receptor antagonist by proopiomelanocortin peptides adrenocorticotropic hormone and beta-endorphin.Neuroimmunomodulation. 1999; 6: 367-372
Published online: September 01, 2010
Accepted: July 27, 2010
Received in revised form: July 24, 2010
Received: March 25, 2010
© 2010 Elsevier B.V. Published by Elsevier Inc. All rights reserved.